XOMA Royalty (NASDAQ:XOMA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of XOMA Royalty (NASDAQ:XOMA) from a hold rating to a buy rating in a research note published on Monday.

XOMA has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and set a $104.00 target price on shares of XOMA Royalty in a research note on Wednesday, May 28th. Benchmark assumed coverage on XOMA Royalty in a research note on Thursday, April 17th. They set a “buy” rating and a $35.00 target price for the company.

XOMA Royalty Stock Up 2.8%

XOMA opened at $27.23 on Monday. The business has a 50 day moving average price of $25.95 and a two-hundred day moving average price of $24.21. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 1.18. The company has a market cap of $325.94 million, a PE ratio of -23.68 and a beta of 1.00. XOMA Royalty has a 52 week low of $18.35 and a 52 week high of $35.00.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.32. The business had revenue of $15.91 million during the quarter, compared to the consensus estimate of $6.75 million. XOMA Royalty had a negative return on equity of 12.43% and a negative net margin of 13.04%. As a group, research analysts anticipate that XOMA Royalty will post -1.41 EPS for the current year.

Insider Activity at XOMA Royalty

In related news, CEO Owen Hughes sold 25,637 shares of the firm’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total value of $650,667.06. Following the completion of the transaction, the chief executive officer directly owned 62,701 shares of the company’s stock, valued at $1,591,351.38. This trade represents a 29.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the firm’s stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $27.10, for a total value of $10,642,793.30. Following the completion of the transaction, the insider directly owned 1,267,545 shares of the company’s stock, valued at $34,350,469.50. The trade was a 23.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On XOMA Royalty

A number of large investors have recently bought and sold shares of XOMA. JPMorgan Chase & Co. grew its holdings in XOMA Royalty by 238.9% during the 4th quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock valued at $318,000 after buying an additional 8,522 shares during the last quarter. Wells Fargo & Company MN grew its holdings in XOMA Royalty by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 1,183 shares during the last quarter. Renaissance Technologies LLC grew its holdings in XOMA Royalty by 89.8% during the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 7,619 shares during the last quarter. Barclays PLC grew its holdings in XOMA Royalty by 13.6% during the 4th quarter. Barclays PLC now owns 12,784 shares of the biotechnology company’s stock valued at $336,000 after buying an additional 1,528 shares during the last quarter. Finally, Eversept Partners LP grew its holdings in XOMA Royalty by 1.2% during the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock valued at $2,508,000 after buying an additional 1,128 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.